Ketoprofen
| Ketoprofen | |
|---|---|
| Salts [] | |
|---|---|
| Potassium ketoprofen | |
| Sodium ketoprofen | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 254.28 g/mol [1] |
| Melting point | 94 °C [1] |
| Solubility | 51 mg/L (at 22 °C) [1] |
| Predicted LogP | 3.1 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C16H14O3 |
| IUPAC name | 2-(3-benzoylphenyl)propanoic acid |
| SMILES | CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O |
| InChI | InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19) |
| InChIKey | DKYWVDODHFEZIM-UHFFFAOYSA-N |
| CAS number | 22071-15-4 |
| UNII | 90Y4QC304K |
| PubChem CID | 3825 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 2–2.5 hours |
| Routes of administration | By mouth, topical, intravenous |
Ketoprofen (also known as 2-(3-Benzoylphenyl)propionic acid, Orudis, Capisten, Oruvail, Actron, Alrheumat, Ketoprofene, Aneol, m-Benzoylhydratropic acid or 3-Benzoylhydratropic acid) is a nonsteroidal anti-inflammatory drug substance of the carboxylic acid class.
Chemistry
Salts []
Stereochemistry []
Ketoprofen is a racemic mixture of the enantiomers (optical activity ( + / - )).
| Stereoisomerism |
|---|
| Stereoisomers from PubChem |
Druglikeness
Lipinski's rule of five
Ketoprofen matches Lipinski's rule of five.Pharmacology
ATC Classification
- musculo-skeletal system (M)
- antiinflammatory and antirheumatic products (M01)
- antiinflammatory and antirheumatic products, non-steroids (M01A)
- propionic acid derivatives (M01AE)
- ketoprofen (M01AE03)
- topical products for joint and muscular pain (M02)
- topical products for joint and muscular pain (M02A)
- antiinflammatory preparations, non-steroids for topical use (M02AA)
- (M02AA10)
- ketoprofen (M02AA10)
MeSH Classification
Mechanism of action []
The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. [1]
Interactions []
Medical side effects []
145 side effects listed on drug labels in SIDER 4.1 (ketoprofen).
- Dyspepsia
- Arrhythmia
- Colitis ulcerative
- Proctocolitis
- Diabetes mellitus
- Gynaecomastia
- Hallucination
- Meningitis aseptic
- Myocardial infarction
- Acute coronary syndrome
- Necrosis
- Nightmare
- Pancreatitis
- Personality disorder
- Sepsis
- Shock
- Dysphoria
- Abdominal pain
- Stomach ache
- Gastrointestinal pain
- Agranulocytosis
- Alopecia
- Amnesia
- Anaphylactic shock
- Anaemia
- Aplastic anaemia
- Angioedema
- Decreased appetite
- Anxiety
- Asthma
- Asthmatic attack
- Bronchospasm
- Colitis
- Infection
- Confusional state
- Feeling abnormal
- Malaise
- Conjunctivitis
- Constipation
- Crohn's disease
- Dermatitis exfoliative
- Diarrhoea
- Dizziness
- Somnolence
- Dysgeusia
- Dyspnoea
- Eczema
- Oedema
- Toxic epidermal necrolysis
- Epistaxis
- Eructation
- Erythema multiforme
- Stevens-Johnson syndrome
- Dermatitis
- Rash
- Asthenia
- Fatigue
- Flatulence
- Flushing
- Gastritis
- Gastrointestinal haemorrhage
- Glossodynia
- Headache
- Cardiac failure
- Cardiac failure congestive
- Haematemesis
- Haematuria
- Haemolysis
- Haemoptysis
- Hepatitis
- Hypersensitivity
- Hypertension
- Hyponatraemia
- Jaundice
- Laryngeal oedema
- Melaena
- Nausea
- Tubulointerstitial nephritis
- Nephrotic syndrome
- Nervousness
- Tension
- Palpitations
- Paraesthesia
- Peptic ulcer
- Pharyngitis
- Pruritus
- Purpura
- Purpuric rash
- Vascular purpura
- Renal failure
- Renal impairment
- Retinal haemorrhage
- Rhinitis
- Salivary hypersecretion
- Convulsion
- Stomatitis
- Mouth ulceration
- Hyperhidrosis
- Tachycardia
- Thirst
- Thrombocytopenia
- Tinnitus
- Urticaria
- Vasodilation procedure
- Vertigo
- Vomiting
- Weight increased
- Weight decreased
- Dry mouth
- Peripheral vascular disorder
- Chills
- Onycholysis
- Hepatic function abnormal
- Sjogren's syndrome
- Hepatitis cholestatic
- Migraine
- Blood urea increased
- Gastrointestinal perforation
- Eye pain
- Skin discolouration
- Intestinal ulcer
- Abdominal pain upper
- Discomfort
- Ill-defined disorder
- Myalgia
- Musculoskeletal discomfort
- Increased appetite
- Proctalgia
- Rectal tenesmus
- Anorectal discomfort
- Menometrorrhagia
- Dermatitis bullous
- Erectile dysfunction
- Rectal haemorrhage
- Photosensitivity reaction
- Gastrointestinal disorder
- Reaction gastrointestinal
- Upper gastrointestinal symptoms
- Affective disorder
- Face oedema
- Visual impairment
- Erythema
- Insomnia
- Deafness
- Hearing impaired
Indications
- Ankylosing spondylitis
- Arthralgia
- Bursitis
- Capsulitis
- Contusion
- Dysmenorrhoea
- Fibromyalgia
- Gout
- Inflammation
- Low back pain
- Osteoarthritis
- Osteoarthritis of cervical spine
- Pain
- Post-traumatic pain
- Postoperative pain
- Primary dysmenorrhea
- Rheumatoid arthritis
- Sciatica
- Sports injury
- Sprain
- Swelling
- Synovitis
- Tendonitis
Subjective effects []
Legal status []
- Australia: Ketoprofen is a S3 / S4.
- Canada: Ketoprofen is Prescription only.[3]
- United States: Ketoprofen is Prescription only.
- Other: Ketoprofen is a Rx-only & OTC.
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 3825, Ketoprofen. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/3825
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Ketoprofen. UNII: 90Y4QC304K. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/90Y4QC304K
Health product highlights 2021: Annexes of products approved in 2021. Health Canada. 3 August 2022. https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-product-highlights-2021/appendices.html
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 08:00:46 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 08:00:42 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 08:00:42 |
| gsrs | ok | 2026-11-20 08:00:43 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015144) | 2026-11-20 08:00:42 |
| kegg | ok | 2026-11-20 08:00:44 |
| pubchem | ok | 2026-11-20 08:00:40 |
| missing (no r/tripreports posts mention it) | 2026-11-20 08:00:42 | |
| sider | ok | 2026-11-20 08:00:42 |
| structure | ok | 2026-11-20 08:00:42 |
| wikipedia | ok | 2026-11-20 08:00:42 |